Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Cancer Biological Therapy Companies

EMEA (Europe, Middle East, and Africa) hosts a plethora of cutting-edge cancer biological therapy companies pioneering innovative treatments. Leaders like Roche, headquartered in Switzerland, focus on groundbreaking monoclonal antibodies, while Germany's Merck KGaA specializes in immuno-oncology. UK-based AstraZeneca excels in targeted therapies, particularly in lung cancer. France's Sanofi is renowned for its diverse oncology portfolio, spanning from immunotherapies to precision medicines.

EMEA Cancer Biological Therapy Key Companies

Latest EMEA Cancer Biological Therapy Companies Update

AstraZeneca and Merck expand collaboration on Lynparza (olaparib) The two pharma giants signed a new agreement to co-develop and commercialize Lynparza for additional cancer indications, potentially expanding its reach to a wider range of patients.

Roche receives EU approval for Tecentriq (atezolizumab) and Avastin (bevacizumab) combination for liver cancer approval marks a significant step forward in treating advanced hepatocellular carcinoma, offering a new option for patients with limited treatment options.

Novartis secures EU approval for Kisqali (ribociclib) in combination with letrozole for advanced breast cancer approval provides a new hormonal therapy option for postmenopausal women with HR+/HER2- advanced breast cancer, potentially improving treatment outcomes.

Sanofi expands CAR-T cell therapy portfolio with acquisition of CellPoint Therapeutics move strengthens Sanofi's position in the promising field of CAR-T therapy, which offers personalized treatment options for various cancers

List of EMEA Cancer Biological Therapy Key Companies in the Market

Bayer AG

Novartis AG

Johnson and Johnson

Pfizer Inc.

Bristol-Myers Squibb Company

Amgen Inc.

AstraZeneca plc.

Celgene Corporation

Engeneic Ltd.

Eli Lily and Company

Merck and Co.

Hoffmann-La Roche Ag.

Teva Pharmaceutical

Cancer Biological Therapy Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.